10-K: Quantumzyme Reports FY2025 Losses, Eyes Enzyme Commercialization

Quantumzyme Corp., an early-stage biotransformation company, reported a net loss of $199,269 for fiscal year 2025 with no revenue, raising substantial doubt about its ability to continue as a going concern.

Summary

• Quantumzyme Corp. is a biotransformation company focused on developing engineered enzymes for active pharmaceutical ingredient (API) production, with plans to expand into fragrance, flavors, sustainable materials, plastic degradation, and carbon capture.
• The company reported no revenues for the fiscal years ended July 31, 2025, and 2024.
• Net loss for the year ended July 31, 2025, was $199,269, an increase from $178,569 in 2024.
• Operating expenses increased to $180,537 in 2025 from $163,593 in 2024, primarily due to higher professional fees.
• The company has engineered its first product, an enzyme for Ibuprofen API production, and is identifying third-party manufacturers and distributors for large-scale production.
• Quantumzyme intends to generate revenue through technology transfer and royalties by licensing its engineered enzymes to major API manufacturers and pharmaceutical companies.
• As of July 31, 2025, the company had a working capital deficit of $440,718 and used $125,181 in cash from operating activities.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern, being entirely dependent on attracting additional funding.
• Disclosure controls and internal control over financial reporting were deemed ineffective as of July 31, 2025, due to a lack of segregation of duties and limited resources.

Sentiment

Score: 2

Explanation: The company is in a very early development stage with no revenue, significant losses, a substantial accumulated deficit, and a working capital deficit. There is substantial doubt about its ability to continue as a going concern, and internal controls are ineffective. While the business concept is aligned with positive industry trends, the financial and operational risks are extremely high.

Positives

• Developed an engineered enzyme for Ibuprofen API production, targeting a greener and more cost-effective manufacturing process.
• The company's solution aligns with ESG investing principles by reducing hazardous chemicals, waste, and energy requirements in chemical manufacturing.
• Strategic plan to license technology and earn royalties, minimizing direct manufacturing and regulatory burdens initially.
• Management team and independent directors possess extensive experience in healthcare, biotech, and life sciences.
• Plans to establish a Scientific Advisory Board with accomplished scientists to drive enzyme engineering advancements.

Negatives

• Reported no revenues for the fiscal years ended July 31, 2025, and 2024.
• Incurred a net loss of $199,269 for the year ended July 31, 2025, an increase from the prior year.
• Accumulated deficit of $5,636,567 as of July 31, 2025.
• Used $125,181 in cash from operating activities for the year ended July 31, 2025.
• Working capital deficit of $440,718 as of July 31, 2025.
• Substantial doubt about the company's ability to continue as a going concern due to net losses, accumulated deficits, and negative operating cash flows.
• Disclosure controls and internal control over financial reporting were deemed ineffective due to material weaknesses, including a lack of segregation of duties and limited resources.
• Currently has only one employee, Mr. Kulkarni, which limits capacity and increases risk of disruption.
• Has not filed for patent protection for its initial Ibuprofen enzyme product, citing costs outweighing anticipated benefits.

Risks

• Financial projections may not be accurate, and investors are cautioned against excessive reliance on them.
• Inability to establish and maintain strategic partnerships on commercially reasonable terms or at all.
• Loss of Mr. Kulkarni, the sole member of the management team, could disrupt operations and growth.
• Inability to hire qualified personnel and retain or motivate key personnel due to intense competition and limited resources.
• Limited workforce of one employee may hinder the ability to execute business objectives, manage product development, regulatory compliance, and business development.
• A decline in general economic conditions could adversely affect operating and financial performance.
• Sole officer and director have limited experience managing a public company, potentially affecting successful operation as a public entity.
• Need for additional capital in the future, which may not be available on favorable terms, if at all, leading to potential dilution of existing stockholders or restrictive debt covenants.
• Failure to raise sufficient funds could force delays or termination of research, development, or commercialization programs.
• Termination or expiration of patent protection for customer APIs could materially and adversely affect revenues due to generic competition.
• Dependence on a limited number of third-party contract manufacturers for large-scale enzyme production, posing risks of difficulties, interruptions, capacity limitations, and delays.
• Lack of formal agreements for off-site testing facilities may disrupt operations, increase costs, and cause delays in product development.
• Competitors with greater resources and experience may develop obsolete products or gain market share.
• Ethical, legal, and social concerns about genetically engineered products and processes could limit or prevent the use of the company's technology.
• Efforts to prosecute, maintain, protect, and defend intellectual property rights may not be successful, and future patents may be challenged or invalidated.
• Risk of third parties claiming infringement, violation, or misappropriation of their intellectual property rights, leading to costly litigation.
• Investors may lose their entire investment due to the company's financial status and going concern doubt.
• Inability to enforce intellectual property rights throughout the world, particularly in foreign countries with weaker IP protection laws.
• Confidentiality and non-use agreements may not adequately prevent disclosures and non-use of trade secrets and other proprietary information.
• Quarterly financial results are expected to fluctuate due to general economic conditions, client acquisition/retention, administrative costs, and marketing costs.
• Dual-class capital structure (Series A with 100 votes/share, Series B with 500 votes/share) limits the ability of other shareholders to influence corporate decisions and may discourage beneficial merger or acquisition attempts.
• Penny stock status impairs trading liquidity and may reduce trading activity.
• Status as an Emerging Growth Company (EGC) and potential Smaller Reporting Company (SRC) allows reduced disclosure, which may make shares less attractive to investors and make it difficult to raise capital.
• Forward-looking statements involve assumptions and risks that could cause actual results to differ materially.
• Potential involvement in litigation, which could consume substantial management time and resources.

Future Outlook

The company intends to expand its engineered enzyme applications beyond API production to sectors like fragrance and flavors, climate-impacting applications (sustainable materials, plastic degradation, carbon capture). It aims to establish itself as an industry leader by solving complex chemistry problems and plans to generate revenue through technology transfer and royalties from licensing its enzymes to major API manufacturers and pharmaceutical companies. Future operations are highly dependent on successful execution of its business plan and obtaining additional financing. The company expects operating expenses to increase as business activities ramp up.

Management Comments

• "As we move forward, we intend to expand beyond the API marketplace and engineer enzymes for the use and deployment in other business sectors such as fragrance and flavors, climate impacting applications like sustainable materials, plastic degradation and carbon capture."
• "Our goal is to help to foster a clean, healthy, and well protected environment supporting a sustainable society and economy."
• "Ultimately, we want to fulfil our vision by developing a focused approach to aid all chemical companies to harness the power of technology by simplifying complex chemistry and reducing the number of steps by implementing scientific rationale like quantum mechanics in biology."
• "Our goal is to bring back manufacturing capabilities in the USA by making the manufacturing of Ibuprofen greener, cost effective and more environmentally friendly."
• "Management believes that it is essential for any company involved in bioengineering activities, including enzyme production, to consult with relevant government agencies and legal experts to ensure compliance with applicable regulations and standards in both the U.S.A. and the U.A.E."
• "We intend to stay informed about updates and changes to regulations that may affect our current and future operations."
• "We believe our success will be in our dedication to our business and scientific principals which will be our key differentiator as we ramp up operations."
• "We believe that, based on our current level of operations, our existing cash, cash equivalents and equity securities will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital if our current plans and assumptions change."

Industry Context

Quantumzyme operates in the dynamic and evolving enzyme engineering industry, a sub-sector of biotechnology focused on modifying enzymes for industrial, medical, and environmental applications. This field is driven by demand for sustainable solutions and leverages advances in genetic engineering, protein design, and computational biology. Key players like Novozymes, DuPont, BASF, Codexis, and Genencor are well-established and significantly better funded. Quantumzyme aims to differentiate itself by offering competitive solutions and focusing on scientific principles, targeting the shift from traditional, hazardous chemical processes to greener, more efficient biocatalysis, particularly in API production like Ibuprofen.

Comparison to Industry Standards

• The company's focus on "clean and green chemistry" and "biocatalysis through engineered enzymes" aligns with a growing industry trend towards sustainability and reduced environmental impact, contrasting with "legacy reactions" that involve hazardous chemicals, high pressure/temperature, and significant waste generation.
• Quantumzyme's initial product, an engineered enzyme for Ibuprofen API production, directly addresses a major issue with traditional Ibuprofen manufacturing, which uses a carcinogenic agent and creates effluent, aiming to make it "greener, cost effective and more environmentally friendly" and potentially bring manufacturing back to the USA.
• Compared to established industry leaders like Novozymes, DuPont Industrial Biosciences, BASF, Codexis, and Genencor, Quantumzyme is an early-stage company with significantly fewer resources, a limited workforce, and no current revenue, putting it at a "significant disadvantage in landing large customer accounts."
• The company's strategy to avoid direct regulatory burdens by licensing to third-party manufacturers is a common approach for early-stage biotech firms, but it relies heavily on the compliance capabilities of its future partners.
• The company's lack of patent protection for its initial product due to cost-benefit analysis contrasts with the industry standard of companies investing in securing intellectual property rights through patents to create a competitive edge.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending or threatened legal proceedings at this time.

Related Party Transactions

• On February 21, 2023, the company acquired assets from Quantumzyme Inc. (a Delaware corporation) and Mr. Naveen Krishna Rao Kulkarni (sole officer, director, and shareholder of Quantumzyme Inc.) in exchange for 150,000,000 restricted shares of the company's common stock issued to Mr. Kulkarni, representing approximately 73% of outstanding shares.
• As of July 31, 2025, and 2024, amounts due to related parties were $17,002 and $15,852, respectively. These amounts are non-interest bearing and due on demand.
• Mr. Kulkarni's Executive Employment Agreement, effective June 1, 2023, includes a base salary of $90,000 per year, 29,500,000 restricted common shares, and 500,000 restricted Series B Preferred Stock.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises (equity offerings). Common stockholders have limited influence due to the dual-class capital structure with superior voting rights for preferred shares. Penny stock status impairs trading liquidity. High risk of complete loss of investment due to going concern doubt and early-stage nature.
• Employees: Currently only one employee (Mr. Kulkarni), who is also the CEO and director. No pension, health, or other benefit plans currently exist. Future hiring is dependent on financial resources.
• Customers (potential): Could benefit from greener, more cost-effective API production methods, such as for Ibuprofen, if the company successfully commercializes its enzymes.
• Suppliers/Contractors: The company relies on third-party manufacturers for large-scale enzyme production and off-site labs for R&D, with risks associated with lack of formal agreements and potential disruptions.
• Creditors: Face risk due to the company's substantial doubt about its ability to continue as a going concern and its significant accumulated deficit and working capital deficit.

Next Steps

• Identify third-party manufacturers and distributors for large-scale production of the Ibuprofen enzyme.
• Understand market needs, demand-supply relationships, technical feasibility, and commercial viability for the Ibuprofen enzyme.
• Engage in discussions with potential end-users regarding the benefits of the proposed Ibuprofen solution.
• Expand enzyme engineering efforts beyond API production to fragrance and flavors, sustainable materials, plastic degradation, and carbon capture.
• Establish strategic partnerships for business growth.
• Hire qualified personnel to expand the workforce and address material weaknesses in internal controls.
• Set up a Scientific Advisory Board with accomplished scientists.
• Formally adopt and implement a Code of Ethics during the fiscal year ending July 31, 2026.
• Appoint at least one director who qualifies as an audit committee financial expert when financial position and staffing permit.
• Seek additional capital through equity offerings, debt financings, credit facilities, and/or strategic collaborations to fund operations and development plans.
• Potentially file and prosecute patent applications to protect intellectual property rights as the business moves forward.

Key Dates

Recommendation

The company is an early-stage entity with no revenue, significant and increasing net losses, a substantial accumulated deficit, and a negative working capital position. There is explicit "substantial doubt about the Company's ability to continue as a going concern." Operations are heavily reliant on a single employee, and internal controls are deemed ineffective due to limited resources. While the underlying technology in enzyme engineering has potential, the current financial health, operational risks, and governance weaknesses present an extremely high-risk investment profile with a high probability of complete loss for investors. The lack of patent protection for its initial product further diminishes its competitive moat.

Keywords

Enzyme Engineering, Biotransformation, Active Pharmaceutical Ingredients (API), Green Chemistry, Sustainable Manufacturing, Biocatalysis, Ibuprofen Production, Quantum Mechanics, Molecular Modeling, Biotechnology, SEC 10-K, Early Stage Company, Going Concern, Intellectual Property Licensing, Emerging Growth Company